# A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

> **NCT06953960** · PHASE1,PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 130 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** ABBV-453
- **DRUG:** Daratumumab
- **DRUG:** Dexamethasone
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT06953960
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-23
- **Primary completion:** 2030-12
- **Final completion:** 2030-12
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06953960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06953960, "A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06953960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*